Madison, Wisconsin: Commercially available CBD-infused products typically contain levels of CBD that differ significantly from the information provided on their labels, according to the data Published in the magazine Epilepsy and behavior.
A team of investigators from the University of Wisconsin’s School of Pharmacy conducted lab analyzes on a variety of commercially available CBD products, including oils, beverages, and foods.
in line with Many else Analytics Of the unregulated and commercially available brand-name CBD products, the investigators reported that the percentage of CBD available in many of the tested products “significantly differs from their label claims.” CBD-containing beverage products were more likely to contain percentages of CBD that differed from their labels.
More than three years later the passage Of the federal legislation legalizing hemp production, the US Food and Drug Administration (FDA) has not yet issued rules regulating the marketing and sale of commercial products containing hemp-derived CBD. speak In October at the National Industrial Cannabis Business Summit in Washington, D.C., FDA Representative (Gail Sipes) He said That the agency cannot move forward with regulations without more data on the safety of CBD products. At that time, I repeated what was stated in the agency situation That companies that market CBD-infused products as nutritional products or as nutritional supplements are in violation of the Food, Drug, and Cosmetic Act.
in a Transfer Regulating over-the-counter CBD products presents a unique challenge because the substance is already available as an FDA-approved drug (Epidiolex), the agency that the Food and Drug Administration submitted to Congress in 2020, said the agency.
NORML and other groups have down urge The US Food and Drug Administration (FDA) to provide regulatory guidance that oversees the production, testing, labeling, and marketing of hemp-derived CBD products.
The full text of the study appears, “Analysis of cannabidiol (CBD) and THC in over-the-counter consumer products: implications for patients and practitioners” in epilepsy and behavior..